DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors. Source
No articles found.
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing d...
Intec Pharma is a clinical-stage biopharmaceuti...
Verrica Pharmaceuticals Inc. is an innovative clinical-stage medical dermatology c...
Verrica Pharmaceuticals Inc. is an innovative c...
Alternaturals, Inc. manufactures and sells alternative healthcare products includi...
Alternaturals, Inc. manufactures and sells alte...
Since Aclaris was founded in 2012, our focus has been innovation to help people wi...
Since Aclaris was founded in 2012, our focus ha...
Sierra Oncology is a clinical stage drug development company advancing targeted th...
Sierra Oncology is a clinical stage drug develo...
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, incl...
Harrow Health, Inc. (NASDAQ: HROW) owns a portf...
ProLung is a medical technology company specializing in innovative predictive anal...
ProLung is a medical technology company special...
Join the National Investor Network and get the latest information with your interests in mind.